<DOC>
	<DOCNO>NCT00664430</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy safety paricalcitol participant moderate severe secondary hyperparathyroidism ( SHPT ) undergo hemodialysis resistant treatment calcitriol .</brief_summary>
	<brief_title>Efficacy Safety Paricalcitol Treatment Secondary Hyperparathyroidism Calcitriol Resistant Dialysis Subjects</brief_title>
	<detailed_description>This multi-center , prospective , open label , one arm , phase IV study design demonstrate paricalcitol efficacy safety treatment moderate severe secondary hyperparathyroidism calcitriol resistant participant dialysis . Following screening , participant begin 8-week controlled calcitriol therapy period . Participants whose parathyroid hormone ( PTH ) level decrease discontinue study . Those whose PTH level decrease begin paricalcitol therapy use dose calculate 0.04 0.1 microgram per kilogram ( mcg/kg ) . Paricalcitol administer intravenously anytime subject ' dialysis . The paricalcitol dose titrate every 2 week iPTH reduce 4 month , adjust monthly 1 year base serum PTH , calcium , phosphorus , albumin measurement .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Male female participant &gt; 18 year age , chronic kidney disease ( CKD ) stage V ; Participants diagnosis calcitriol resistance define : Episodes hypercalcemia and/or hyperphosphatemia ( defined episode calcium phosphorus Upper Limit Normal document medical history state treatment calcitriol discontinue due hypercalcemia and/or hyperphosphatemia ) preclude treatment continuation and/or persistent PTH 600pg/mL calcitriol therapy ; PTH value screen visit 600 pg/mL 2,000 pg/mL ; Stable clinical condition ; Participant voluntarily consent participate study , sign date informed consent form , approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) , nature study explain question study elucidate . The informed consent must sign studyspecific procedure perform . Previous parathyroidectomy ; Presence hypercalcemia ( correct Ca &gt; 10.5 mg/dL ) and/or hyperphosphatemia ( P &gt; 6.0 mg/dL ) and/or Ca x P product &gt; 60 , screen visit ( correct Ca calculate : [ 4 participant 's serum albumin ( g/dL ) ] x 0.8 + participant 's serum Ca value ) ; Severe and/or unstable clinical condition , e.g. , congestive heart failure , advanced cancer , advance HIV disease , severe endocrinopathies , uncompensated diabetes mellitus , lifethreatening cardiac arrhythmia , etc ; Abnormal liver test ( &gt; 1.5 time upper limit normal ) ; Pregnant breastfeed woman ; Evidence vitamin D toxicity ; Known hypersensitivity study drug component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Dialysis</keyword>
	<keyword>Calcitriol Resistant</keyword>
	<keyword>Secondary Hyperparathyroidism</keyword>
</DOC>